Eli Lilly (LLY) vs Novartis (NOVN)
Eli Lilly (LLY) and Novartis (NOVN) side by side: both in Healthcare, listed on New York Stock Exchange and SIX Swiss Exchange. Eli Lilly is the larger of the two by approximate market capitalization (about 3.8×).
| Field | Eli Lilly | Novartis |
|---|---|---|
| Legal name | Eli Lilly and Company | Novartis AG |
| Ticker | LLY | NOVN |
| Exchange | New York Stock Exchange XNYS | SIX Swiss Exchange XSWX |
| Jurisdiction | United States | Switzerland |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Market cap ≈ | $1.1tn | $292.4bn |
| Founded | 1876 | 1996 |
| Reporting currency | USD | CHF |
| LEI | FRDRIPF3EKNDJ2CQJL29 | 5493007HIVTX6SY6XD66 |
| ISIN | US5324571083 | CH0012005267 |
| FIGI | BBG001S5STL8 | BBG001SD31N7 |
| Index membership | S&P 500 | — |
| Held by (covered funds) | 1 | — |
Eli Lilly
Pharmaceutical maker; GLP-1 metabolic drugs (Mounjaro, Zepbound), oncology and neuroscience.
Novartis
Basel-based pharmaceutical company created by the 1996 merger of Ciba-Geigy and Sandoz, now a pure-play innovative-medicines business after spinning off Alcon and Sandoz. Key franchises include cardiovascular, oncology and immunology drugs.
Market caps are computed from each issuer's own filed share count times the close on 2026-08-28, not copied from a vendor; LEI from GLEIF (CC0), ISIN read from each issuer's own primary listing document with its ISO 6166 check digit validated, FIGI from OpenFIGI, MIC from the ISO 10383 registry — full provenance on Sources. Not real-time, not investment advice. Both sides as data: /api/v1/companies/eli-lilly · /api/v1/companies/novartis